Palazestrant joins vepdegestrant in pivotal development, as SERDs continue their rollercoaster ride.

Phase 1 data for divarasib in lung and colorectal cancers look good versus Lumakras and Krazati’s earlier showings.

A statistical analysis of Skyscraper-01’s second interim read is inadvertently posted on a Roche website.

However, the design of the Contact-02 study, and the relevance of the positive PFS endpoint, will be debated.

PD-(L)1 players are increasingly looking to subcutaneous delivery to maintain market share, and next month brings a major catalyst.

Liver toxicity notwithstanding, volrustomig will start a phase 3 lung cancer study versus Keytruda imminently.

After generating unexpectedly positive TIGIT data Roche moves to launch a phase 3 trial.